TMEFF2 Deregulation Contributes to Gastric Carcinogenesis and Indicates Poor Survival Outcome
Tiantian Sun(Renji Hospital), Jing‐Yuan Fang(Shanghai Institute of Hematology), Hua Xiong(Shanghai Jiao Tong University), Jie Hong(Shanghai Jiao Tong University), Wenxin Qin(Renji Hospital), Huijun Zhao(Ministry of Education of the People's Republic of China), Wan Du(University of Michigan), Haoyan Chen(Shanghai Jiao Tong University), Linlin Ren(Chinese Academy of Sciences), Yong‐Bing Xiang(Chinese University of Hong Kong), Yingchao Wang(China University of Mining and Technology), Weiping Zou(University of Michigan), Jie Xu(Shanghai Jiao Tong University), Yurong Weng, Yingxuan Chen(Renji Hospital), Yanan Yu(Beijing Institute of Technology), Weibiao Cao(Jiangsu University)
Cited by 42
Related Papers
Comprehensive review of targeted therapy for colorectal cancer
|Signal Transduction and Targeted Therapy|2020|1.7k
Type I and II Endometrial Cancers: Have They Different Risk Factors?
|Journal of Clinical Oncology|2013|833
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
|Current Opinion in Immunology|2013|740
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
|Journal of Clinical Investigation|2018|598